MIRCERA.com

MIRCERA® has a proven high success rate in correcting anaemia in erythropoiesis-stimulating agent (ESA)-naive patients on dialysis and not on dialysis.^1–3 Target haemoglobin (Hb) levels are achieved in up to 97.5% of patients not on dialysis treated with subcutaneous (SC) MIRCERA (every 2 weeks).^1,3 Comparable results were achieved with intravenous (IV) MIRCERA in patients on dialysis (response rate 93.3%).^2,3 The median dose of MIRCERA at time of response was 0.6 mg/kg every 2 weeks.^1,2

 

Smooth and steady rise in haemoglobin level
MIRCERA provides a smooth and steady rise in Hb levels (see Figure), minimising the risk of exceeding a rate of increase greater than 2 g/dL in 1 month.^1–3

 

 

Mean haemoglobin levels in patients with chronic kidney disease not on dialysis during correction and evaluation phase of treatment with MIRCERA or darbepoetin alfa.¹

 

Fewer patients exceed an Hb level of 13 g/dL during correction with MIRCERA than during correction with darbepoetin alfa (12% vs 34%, p<0.0001) in the first 8 weeks (see Figure).¹

 

 

Patients with at least 1 haemoglobin excursion >13 g/dL during first 8 weeks of treatment with MIRCERA or darbepoetin alfa.¹

 

References:

 

1. Macdougall IC, Walker R, Provenzano R, et al. C.E.R.A. corrects anaemia in patients with chronic kidney disease not on dialysis: Results of a randomized clinical trial. Clin J Am Soc Nephrol. 2007 In press.
2. Klinger M, Aria M, Vargemezis V, et al. Intravenous pegzerepoetin alfa, a continuous receptor activator (C.E.R.A.), administered twice monthly corrects haemoglobin levels in patients with chronic kidney disease on dialysis: results of AMICUS, a randomized prospective study vs epoetin given once to three times weekly. Am J Kidney Dis. 2007 In press.
3. MIRCERA® Summary of Product Characteristics. F. Hoffmann-La Roche Ltd. 2007.